A pooled analysis of the efficacy of anti-HER2 drugs in the treatment of patients with HER2 mutated cancers of any site noted response rates of 60.0% for T-DXd, 31.0% for pyrotinib, 26.0% for neratinib combined with trastuzumab, 25.0% for neratinib combined with fulvestrant, 19.0% for trastuzumab combined with pertuzumab, and 16.0% for neratinib (Zheng et al., 2023). The gene discussed is ERBB2; the disease is cancer.